Eurofins Scientific (ERF) Q4 2025 earnings summary

Executive summary

• Achieved or exceeded all FY 2025 objectives, including 24% EPS growth, 5% revenue growth, margin expansion, and strong free cash flow, confirming 2027 targets and marking the third year of a five-year strategic plan.

• Organic growth accelerated through the year, with Q4 showing the highest rate; robust performance in life businesses, while BioPharma and Clinical Diagnostics improved in Q4 despite market headwinds.

• Significant investments in automation, AI, digital solutions, and network expansion are driving improved operating leverage and margins, with major IT and site investments expected to be largely completed by 2027.

• All regular capex and M&A investments were fully funded by operating cash flow, with surplus after investments.

• 2027 objectives reaffirmed, with further EBITDA margin and cash flow progress expected in 2026.

Financial highlights

• Revenues rose 5% year-over-year to €7,296m, with organic growth of 3.7%–4.1%.

• Adjusted EBITDA increased 6% to €1,641m, margin up to 22.5%; reported EBITDA up 8% to €1,561m, margin up 70bps to 21.4%.

• Basic EPS up 24% to €2.31; net profit up 17% to €473m.

• Free cash flow to the firm before investment in owned sites up 12% to €1,071m.

• Share buybacks of €540m completed, with over €1.5bn returned to shareholders since 2021.

Outlook and guidance

• FY 2026 targets mid-single-digit organic growth and €250m in annualized acquisition revenues.

• Adjusted EBITDA margin expected to improve further, with SDI at EBITDA level to decline; 2027 objectives reaffirmed (24% EBITDA margin, >50% cash conversion, 6.5% organic growth).

• CapEx to remain around €400m/year, with €200m/year for owned sites in 2026–2027; major IT investments to be largely completed by 2027.

• Free cash flow and cash conversion expected to grow.